Contact Us

Medtronic Infuse Bone-Growth
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date when device was implanted :

Please describe any problems or injuries caused by the product:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Medtronic Infuse

medtronic infuse bone graft side effects, potential lawsuits

Medtronic Infuse Bone Graft Becomes Controversial Due to Safety Concerns about its Side Effects

Medtronic Infuse Bone Graft Becomes Controversial Due to Safety Concerns about its Side Effects

Medtronic Infuse Bone Graft Becomes Controversial Due to Safety Concerns about its Side Effects

Medtronic Infuse is a medical device that is supposed to help re-grow bone in the spine, but it has become controversial because of safety concerns. Infuse has been linked to side effects such as cancer, male sterility and, excess bone. Most recently, in November 2013, a report posted on the National Center for Biotechnology Information(NCBI) website indicated that Medtronic’s Infuse bone graft product likely caused a life-threatening problem during revision surgery. Specifically, the report said that Infuse partially contributed to fibrosis and scarring that caused the iliac vein to adhere to the area of the patient’s spine that had been previously operated on, resulting in a life-threatening vascular injury during revision surgery.

“Spine surgeons should be aware of this potential inflammatory fibrosis in addition to other reported complications related to rhBMP-2,” the authors noted.

Such complications seem to appear even more when the product is used off-label for unapproved procedures. To make matters worse, it appears that Medtronic has bribed doctors to hide the side effects associated with Infuse. Our firm has been handling defective drug and medical device issues for years, and is actively investigating Infuse cases. If you’ve had a procedure with Infuse, we’d like to hear from you. Call us today for free, no-obligation legal advice.

Side Effects Linked to Off-Label Use

Infuse contains recombinant human Bone Morphogenetic Protein-2 (rhBMP-2), a protein that stimulates bone growth. It is mostly meant for a type of spine surgery called lumbar fusion. The U.S. Food and Drug Administration (FDA) has only approved Infuse for anterior approach lumbar fusion, which is performed through the front of the body. Infuse is not approved for posterior lumbar fusion, which is performed through the back. Infuse has also been cleared for two types of dental surgery.

A drug or medical device is used “off-label” when it is used in ways not covered by its formal FDA approval. It is not illegal for doctors to use medicinal products off-label as they see fit, but it is illegal for companies to promote such uses. Infuse complications are the most prevalent in off-label procedures, such as when it is used in the cervical spine (neck). In fact, the FDA has warned that using Infuse in the cervical spine could lead to life-threatening complications, including swelling of the neck and throat.

Additional side effects and complications associated with Infuse include:

  • Cancer
  • Difficulty swallowing
  • Difficulty breathing
  • Difficulty speaking
  • Ectopic or uncontrolled bone growth near the site of the surgery
  • Nerve injuries that lead to severe, chronic pain
  • Ongoing or chronic pain that radiates in the arms or legs
  • Male sterility (retrograde ejaculation)
  • Cauda equina syndrome (CES)

Did Medtronic Hide Infuse Complications?

Medtronic Infuse Bone Graft became even more controversial in June 2011 when a group of spine experts publicly denounced research funded by the company in a study published in the Spine Journal. The authors of that study alleged that Medtronic studies on Infuse failed to report side effects, such as cancer, sterility in men, infections, bone dissolution and worsened back and leg pain. Contrary to what the Medtronic studies suggest, the Spine Journal researchers found that these complications occurred in 10 to 50 percent of patients who received Infuse in 13 Medtronic-funded trials conducted between 2000 and 2010. The review also questioned the financial relationship between the company and the researchers who did the studies; the median amount paid to the doctors was between $12 million and $16 million per study, although none of the royalty payments were related to Infuse.

A government investigation found evidence that the Medtronic-funded studies were biased. According to a United States Senate Finance Committee report, Medtronic employees helped write and edit 11 out of the 13 studies. This “ghostwriting” is not illegal, but it is considered a serious breach of integrity in the scientific community.

Judge Denies Medtronic’s Motion to Dismiss a Lawsuit Brought Over Infuse

In a recent consolidated class action lawsuit being tried in the U.S. District Court for the District of Minnesota and brought against Medtronic Inc. over its Infuse product, the judge denied Medtronic’s Motion to Dismiss. West Virginia Pipe Trades Health & Welfare Fund, Employees’ Retirement System of the State of Hawaii, and Union Asset Management Holding AG brought the lawsuit; the Court’s denial was made on September 29, 2014.

The allegations in this lawsuit include that Medtronic and some of its former and current officers, consultants, and executives were engaged in a scheme meant to mislead investors concerning Medtronic’s financial position, specifically concerning Infuse’s safety and efficacy. Allegations also include that initial studies showing the product’s safety and efficacy were shown to be inaccurate based on newer studies published in May and June 2011 in The Spine Journal. The journal article revealed that the incidence of Infuse adverse events was 10-50 times greater than previously published rates.

Other allegations include that Medtronic, in collaboration with physician consultants, were involved in a scheme to defraud investors by manipulating the initial studies. Because of this scheme to defraud, Medtronic’s stock traded at falsely inflated prices during the Class Period, dropping nearly 25 percent from its highest level once the truth was revealed, according to lawsuit allegations.

The lawsuit cited violations of the Securities and Exchange Act; a scheme and course of conduct intended to mislead; and violations of the Exchange Act.

Contact Us

If you or a loved one suffered any of the above injuries after undergoing a procedure with Medtronic Infuse, you may have valuable legal rights. To learn more about how our personal injury attorneys can help you, please fill out our online form or call us at 1-800-YOURLAWYER (1-800-968-7529).


Medtronic InfuseRSS Feed

Medtronic Infuse Shareholder Lawsuit Reinstated

Dec 30, 2016
WE ARE NO LONGER TAKING CASES FOR DEFECTIVE MEDTRONIC INFUSE DEVICES Investment Funds Lawsuit Against Medtronic Reopened A federal appeals court just reinstated litigation from investment funds that alleged the medical device maker, Medtronic Inc., misled investors and physicians by hiding known risks from its very debated Infuse bone graft product. The move creates a legal obstruction for Medtronic. Medtronic's marketing of Infuse has long been the focus of mounting controversy over the...

Federal Data Shows Doctors Received Large Payments from Minnesota Device Makers

Jul 6, 2015
Medical device companies in Minnesota made large payments to handfuls of doctors, Star Tribune reports. Newly released federal data looking at payments $1 million or greater indicates that Medtronic PLC and St. Jude Medical paid a total of $81 million to eight doctors across the country. The federal Open Payments database for 2014, which was published Tuesday, shows that Minnesota device makers paid over $211 million to doctors and hospitals for reasons not related to research. This is the...

Fortune 500 Drops Corporations that Move Their Domiciles from U.S.

Jun 18, 2015
The newest iteration of the Fortune 500—the list of the top 500 U.S. closely held and public corporations—does not include the medical device-maker Medtronic or the drug maker Mylan. Fortune removed the two companies from its prestigious list for moving their domiciles out of the United States for tax purposes while continuing to be run from here, the Washington Post reports. Medtronic would have ranked 185 on the list and Mylan 368. Standard & Poor's 500 Index continues to...

Medtronic Faces Lawsuits from 1,000 Infuse Patients, More Expected

Mar 5, 2014
Medtronic is being sued by over 1,000 patients who received its Infuse bone graft product. Additionally, several states are now investigating the sales and marketing practices involving Infuse. The bone morphogenetic protein-2 (BMP-2) product is used to stimulate bone growth in spine surgery, but for a decade it has been the center of scientific and legal controversy. The company said in a securities filing that it was facing 700 lawsuits involving about 1,000 people at the end of its fiscal...

Senate investigation details Medtronic's influence on clinical data

Dec 10, 2012
A Senate investigation has confirmed that medical device maker Medtronic Inc. paid hundreds of millions of dollars to influence clinical data on its INFUSE bone growth product. According to a Milwaukee Journal Sentinel report, the Senate Committee on Finance determined that Medtronic paid at least $210 million to a group of 13 doctors over the course of 15 years. This money and other rewards were given in exchange for favorable data used to get INFUSE approved by the Food and Drug...

More Medtronic Infuse News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo